Pre-surgical targeted molecular therapy in renal cell carcinoma

Vitaly Margulis, Christopher G. Wood

Research output: Contribution to journalShort surveypeer-review

14 Scopus citations


Pre-surgical systemic therapy with targeted molecular agents is an attractive option as an approach to the treatment of patients with renal cell carcinoma. This treatment strategy offers a rational approach for selecting patients with metastatic disease who are most likely to benefit from cytoreductive nephrectomy, but also allows access to treated tumour tissue to study the molecular mechanisms of response and resistance. In patients with locally advanced disease, this strategy offers the potential for improved resectability and timely delivery of systemic therapy to treat subclinical metastatic disease. Preliminary evidence indicates that the use of targeted therapies before nephrectomy is safe. Reliable therapy-specific prognostic biomarkers are needed for the optimal integration of aggressive surgical intervention and systemic therapy to maximize the oncological benefits for the patient.

Original languageEnglish (US)
Pages (from-to)150-153
Number of pages4
JournalBJU international
Issue number2
StatePublished - Jan 2009


  • Prognostic factors
  • Renal cell carcinoma
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Pre-surgical targeted molecular therapy in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this